Open | - |
Close | - |
Volume / Avg. | 421.000 / 643.701K |
Day Range | - - - |
52 Wk Range | 26.320 - 42.995 |
Market Cap | $19.414B |
P/E Ratio | 30.811 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 52 |
Short Interest | 0.35% |
Days to Cover | 3.05 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Genmab (NASDAQ: GMAB) through any online brokerage.
Other companies in Genmab’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Genmab (NASDAQ: GMAB) was reported by HC Wainwright & Co. on Wednesday, March 6, 2024. The analyst firm set a price target for 50.00 expecting GMAB to rise to within 12 months (a possible 68.07% upside). 34 analyst firms have reported ratings in the last year.
The stock price for Genmab (NASDAQ: GMAB) is $29.75 last updated Today at March 19, 2024 at 4:43 AM EDT.
There are no upcoming dividends for Genmab.
Genmab’s Q1 earnings are confirmed for Wednesday, May 8, 2024.
There is no upcoming split for Genmab.
Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.